Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics.

Cell reports - 31 Mar 2020

Santana-Codina Naiara, Chandhoke Amrita Singh, Yu Qijia, Małachowska Beata, Kuljanin Miljan, Gikandi Ajami, Stańczak Marcin, Gableske Sebastian, Jedrychowski Mark P, Scott David A, Aguirre Andrew J, Fendler Wojciech, Gray Nathanael S, Mancias Joseph D

Abstract excerpt

Covalent inhibitors of the KRASG12C oncoprotein have recently been developed and are being evaluated in clinical trials. Resistance to targeted therapies is common and may limit long-term efficacy of KRAS inhibitors (KRASi). To identify pathways of adaptation to KRASi and predict drug combinations that circumvent resistance, we use mass-spectrometry-based quantitative temporal proteomics to profile the proteomic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Proliferation
Share to Down-Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms

Share to Oncogenes

Share to Proteome

Share to Proteomics

Share to Proto-Oncogene Proteins p21(ras)

Share to Up-Regulation

Source

Identifiers

PMID: 32234489
DOI: 10.1016/j.celrep.2020.03.021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics.PMID 32234489Read ↗

Defining and targeting adaptations to oncogenic KRAS <sup>G12C</sup> inhibition using quantitative temporal proteomicsSemantic proximity Read ↗

Cell Type-specific Adaptive Signaling Responses to KRASG12C Inhibition.Semantic proximity Read ↗

Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of SotorasibSemantic proximity Read ↗

Addicted to proteostasis: How KRAS-driven cancers acquire resistance to clinical KRAS inhibitors.Semantic proximity Read ↗

Oncogenic mutations of KRAS modulate its turnover by the CUL3/LZTR1 E3 ligase complex.Semantic proximity Read ↗

Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.Semantic proximity Read ↗

Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer.Semantic proximity Read ↗

Metabolomic, Proteomic, and Single-Cell Proteomic Analysis of Cancer Cells Treated with the KRASG12D Inhibitor MRTX1133.Semantic proximity Read ↗

A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies.Semantic proximity Read ↗

Interplay Between KRAS and LZTR1 Protein Turnover, Controlled by CUL3/LZTR1 E3 Ubiquitin Ligase, is Disrupted by KRAS MutationsSemantic proximity Read ↗

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.Semantic proximity Read ↗

KRAS G12C-mutant driven non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.